Education
About Us
Working with TipRanks
Follow Us
Haleon PLC Sponsored ADR (HLN)
NYSE:HLN
HLN Stock Chart & Stats
$9.52
$0.04(0.37%)
At close: 4:00 PM EST
$9.52
$0.04(0.37%)
Day’s Range― - ―
52-Week Range$8.71 - $11.42
Previous CloseN/A
Volume6.87M
Average Volume (3M)8.22M
Market Cap
$45.40B
Enterprise Value$41.82B
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$8.59B
Price to Earnings (P/E)20.6
Beta0.11
Next Earnings
Jul 30, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield1.74%
Share Statistics
EPS (TTM)0.13
Shares Outstanding4,454,192,400
10 Day Avg. Volume10,244,866
30 Day Avg. Volume8,218,669
Financial Highlights & Ratios
PEG Ratio1.65
Price to Book (P/B)2.05
Price to Sales (P/S)3.12
P/FCF Ratio17.06
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda14.80
Forecast
1Y Price Target
$13.86Price Target Upside45.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.56
Revenue Forecast (FY)$15.50B
Bulls Say, Bears Say
Bulls Say
Margin ImprovementSustained margin expansion reflects structural supply‑chain and productivity gains that improve earnings resilience. Higher gross and net margins create durable cash coverage for reinvestment, protecting profitability even if top‑line growth lags.
Strong Cash GenerationHigh FCF conversion and a large cash uplift provide lasting financial flexibility: they fund capex, A&P/R&D, and debt reduction without relying on equity markets, cushioning the business through cyclical volume weakness.
Brands & E‑commerce StrengthA portfolio of leading OTC brands plus strong e‑commerce reach creates durable competitive advantage. High online share and channel capabilities support margin, direct consumer access, and faster scaling in high‑growth markets like China.
Bears Say
Soft Revenue & VolumesPersistent low volume growth forces reliance on price/mix and marketing to hit targets. Structural volume underperformance versus peers limits sustainable top‑line momentum and increases sensitivity to category cycles and private‑label pressure.
Significant Absolute DebtA large absolute debt stock reduces strategic flexibility and raises refinancing risk if growth stalls. Debt servicing and covenant considerations constrain investment choices and make the business more sensitive to macro shocks.
U.S. And Pharmacy Channel HeadwindsStructural weakness in the U.S. and uncertainty in pharmacy channels (destocking, retailer changes) impair the company's largest market. Persistent channel disruption raises execution risk and could depress sell‑through and distributor relationships.
Haleon PLC Sponsored ADR News
HLN FAQ
What was Haleon PLC Sponsored ADR’s price range in the past 12 months?
Haleon PLC Sponsored ADR lowest stock price was $8.71 and its highest was $11.42 in the past 12 months.
What is Haleon PLC Sponsored ADR’s market cap?
Haleon PLC Sponsored ADR’s market cap is $45.40B.
When is Haleon PLC Sponsored ADR’s upcoming earnings report date?
Haleon PLC Sponsored ADR’s upcoming earnings report date is Jul 30, 2026 which is in 146 days.
How were Haleon PLC Sponsored ADR’s earnings last quarter?
Haleon PLC Sponsored ADR released its earnings results on Feb 25, 2026. The company reported $0.129 earnings per share for the quarter, beating the consensus estimate of $0.124 by $0.005.
Is Haleon PLC Sponsored ADR overvalued?
According to Wall Street analysts Haleon PLC Sponsored ADR’s price is currently Undervalued.
Does Haleon PLC Sponsored ADR pay dividends?
Haleon PLC Sponsored ADR pays a Quarterly dividend of $0.059 which represents an annual dividend yield of 1.74%. See more information on Haleon PLC Sponsored ADR dividends here
What is Haleon PLC Sponsored ADR’s EPS estimate?
Haleon PLC Sponsored ADR’s EPS estimate is 0.29.
How many shares outstanding does Haleon PLC Sponsored ADR have?
Haleon PLC Sponsored ADR has 4,454,192,400 shares outstanding.
What happened to Haleon PLC Sponsored ADR’s price movement after its last earnings report?
Haleon PLC Sponsored ADR reported an EPS of $0.129 in its last earnings report, beating expectations of $0.124. Following the earnings report the stock price went down -5.776%.
Which hedge fund is a major shareholder of Haleon PLC Sponsored ADR?
Currently, no hedge funds are holding shares in HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.86 (45.59% Upside)
$13.86 (45.59% Upside)
Blogger Sentiment
Neutral
HLN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.22%
12-Months-Change
Fundamentals
Return on Equity
10.38%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
Haleon PLC Sponsored ADR
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
HLN Company Deck
HLN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances clear operational and strategic progress (notably strong margin/cost improvements, Oral Health outperformance, emerging markets growth, increased A&P/R&D investment, and a planned $175–$200M cost saving reorganization) against meaningful top-line and volume challenges (soft U.S. market, cold & flu season weakness, category-specific headwinds, and regional retailer/inventory issues). Management presented realistic 2026 guidance (3%–5%) while reiterating confidence in returning to the 4%–6% medium-term ambition as U.S. performance, distribution gains, and productivity benefits materialize.View all HLN earnings summariesHLN Stock 12 Month Forecast
Average Price Target
$13.86
▲(45.59% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Ownership Overview
―
Insiders
4.37% Mutual Funds
5.19% Other Institutional Investors
90.24% Public Companies and
Individual Investors